InterMune, Inc.
Chiron grants nonexclusive license for HCV therapeutics
Published in Medicine and Law Weekly, October 15th, 2004
Financial terms of the agreement were not disclosed.
"We are pleased to have worked with InterMune to reach this agreement," said Ursula Bartels, Chiron's general counsel. "Making our HCV technology available to develop small-molecule therapeutics will help to address the toll from this terrible disease. Chiron is committed to meeting this major medical need, both through its broad licensing policy and through its own small-molecule therapeutic program."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- OptoQ AB
Medical technology company signs agreement with Fresenius Medical Care - Albert Einstein College of Medicine
Cryptococcus glucuronoxylomannan IgM have diverse gene use profiles - Alnylam Pharmaceuticals, Inc.
Pharmaceutical company appoints Robert Millman as chief patent counsel - American Association for Homecare
Fee-for-service rates for oxygen nearly the same as Medicare rates, study shows - Androclus Therapeutics
Biotech firm granted patent for artificial antigen presenting cells - Bristol-Myers Squibb
Settlement awards $11.3 million to U.S. government for Medicaid expenses - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
